Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration

2022-10-28

Page View：

On October 19, AnDiCon Bio (AnDiCon) officially launched the phase II/III clinical study of ADC189 tablets, a new class 1 anti-influenza drug. The drug is expected to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China.

AnDiCon Bio and Medicilon-1.jpg

It is worth mentioning that ADC189 will also add new research on pediatric indications while starting the clinical phase II/III trial. Shanghai Medicilon Inc (Medicilon) is fortunate to undertake the formulation R&D of ADC189, helping the class 1 anti-influenza new drug ADC189 to benefit more patients.

Reference:
Pharmaceutical Research CDMO Service Platform
To assist preclinical research of RNA drugs, Medicilon and Acon Pharmaceuticals reached a strategic collaboration
Antibody-Drug Conjugate(ADC) Platform

ADC189 has launched clinical phase II/III, which is an important breakthrough in the field of anti-infection of the respiratory tract in China, and is also a testimony to the independent R&D strength of AnDiCon. Medicilon, which also focuses on innovation, has vigorously entered the CDMO field in recent years. Currently, Medicilon preparation CDMO can undertake the whole process of preparation R&D from project evaluation, pre-prescription research, preparation process research, quality research, clinical sample production, stability research and registration, which assist the R&D of innovative drugs. A number of innovative drugs have completed formulation development, which were successfully approved for clinical use, through Medicilon's high-end formulation technology platforms, such as inhalation drug research and development platform, ophthalmic drug research and development platform, and topical skin preparation research and development platform.

Up to now, Medicilon has undertaken more than 100 IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins. As of May 2022, Medicilon has successfully helped 10 ADC drugs to be approved for clinical trails, and has multiple ADC projects under development. Medicilon has in-depth exchanges with customers in the formulation of the preclinical integrated research plan of ADC. The backbone of scientific research combines the characteristics of each case with years of practical experience and technical accumulation, and carefully submits high-quality experimental plans and results to customers.

About AnDiCon

Led by a number of top domestic scientists and academicians, AnDiCon has an efficient and pragmatic project team with an international perspective. Relying on the platform advantages of the company's DMPK new drug discovery platform, AnDiCon is committed to solving the accessibility of innovative drugs in the field of respiratory anti-infection and gynecology in China. AnDiCon's product pipeline also includes urgently needed oral new drugs for endometriosis and uterine fibroids, 3CL protease inhibitory anti-COVID-19 drugs, and anti-RSV drugs. As a leading Biotech company in the field of respiratory anti-infection and gynecology, AnDiCon has been recognized by many well-known investment institutions.

❖ Medicilon’s preparation services

Medicilon's preparation laboratory and workshop area is about 4,000 square meters, with 100 professional R&D teams, of which more than 40% are masters/doctors, and more than 95% are undergraduates. The team has rich experience in successful research and development of innovative drugs, consistency evaluation, and improved new drugs, and experience in China-US dual filing and project management. The Medicilon pharmaceutical preparation R&D team has successfully cooperated with well-known large and medium-sized pharmaceutical companies worldwide, and has accumulated 18 years of experience in the research and application of innovative drugs and generic drugs. We provide one-stop and systematic preparation R&D services covering innovative drugs and generic drugs to meet the needs of customers at different stages of R&D.

andicon CDMO adc

Return

Relevant News

Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use

2022-05-05

Recently, Bio-Thera Solutions, Ltd. (Bio-Thera) has been approved for clinical application of BAT8006 for injection.

Medicilon Helps Hangzhou Dac Biotechnology Muc1-ADC Get Clinical Approval

2021-07-06

Recently, a recombinant humanized anti-MUC1 monoclonal antibody-Tub201 coupling agent (hereinafter referred to as "Muc1") for the treatment of advanced solid tumor class 1 ADC drug injection from Dac Biotechnology was approved for clinical use. This is the first clinically approved Muc1-ADC drug in China.

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

2020-07-20

On July 20, 2020, DAC Biotech's new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue.Read more